NASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis $18.08 -0.09 (-0.50%) (As of 12:45 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Corbus Pharmaceuticals Stock (NASDAQ:CRBP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Corbus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$17.80▼$18.4050-Day Range$15.96▼$56.2852-Week Range$3.70▼$61.90Volume84,530 shsAverage Volume571,075 shsMarket Capitalization$220.20 millionP/E RatioN/ADividend YieldN/APrice Target$65.86Consensus RatingBuy Company OverviewCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Read More… Is Your 401(k) Safe? The Real Risk No One Sees Coming (Ad)Every day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopping, and the digital dollar is coming. You can protect yourself—but only if you act now. Don't wake up too late. Get your Digital Dollar Protection today and secure your retirement before the window closes.Click Here For Your Free Guide Corbus Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks97th Percentile Overall ScoreCRBP MarketRank™: Corbus Pharmaceuticals scored higher than 97% of companies evaluated by MarketBeat, and ranked 51st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorbus Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Corbus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($4.25) to ($6.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Corbus Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted20.17% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently decreased by 13.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.65 Percentage of Shares Shorted20.17% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently decreased by 13.45%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.35 News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Corbus Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for CRBP on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows9 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,003,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Stock News HeadlinesCorbus Pharmaceuticals (CRBP) Receives a Buy from RBC CapitalNovember 9, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors despite daily gainsNovember 9, 2024 | marketwatch.comDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. November 14, 2024 | Crypto 101 Media (Ad)We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn RateNovember 9, 2024 | finance.yahoo.comCorbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 8, 2024 | uk.finance.yahoo.comCorbus Pharmaceuticals Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comCorbus Pharmaceuticals Reports Q3 2024 Financials and UpdatesNovember 8, 2024 | markets.businessinsider.comCorbus Pharmaceuticals presents new CRB-913 pre-clinical data at Obesity WeekNovember 5, 2024 | markets.businessinsider.comSee More Headlines CRBP Stock Analysis - Frequently Asked Questions How have CRBP shares performed this year? Corbus Pharmaceuticals' stock was trading at $6.04 on January 1st, 2024. Since then, CRBP stock has increased by 201.0% and is now trading at $18.18. View the best growth stocks for 2024 here. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.19) by $0.29. Who are Corbus Pharmaceuticals' major shareholders? Top institutional investors of Corbus Pharmaceuticals include Assenagon Asset Management S.A. (2.07%), Charles Schwab Investment Management Inc. (0.78%), HealthInvest Partners AB (0.58%) and abrdn plc (0.25%). Insiders that own company stock include Yuval Cohen, Sean F Moran and Craig Stuart Millian. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Pfizer (PFE). Company Calendar Last Earnings8/06/2024Today11/14/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/11/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRBP CUSIPN/A CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees40Year Founded2009Price Target and Rating Average Stock Price Target$65.86 High Stock Price Target$88.00 Low Stock Price Target$40.00 Potential Upside/Downside+265.7%Consensus RatingBuy Rating Score (0-4)3.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.28% Return on Assets-32.92% Debt Debt-to-Equity RatioN/A Current Ratio13.84 Quick Ratio13.84 Sales & Book Value Annual Sales$880,000.00 Price / Sales249.25 Cash FlowN/A Price / Cash FlowN/A Book Value$12.36 per share Price / Book1.46Miscellaneous Outstanding Shares12,179,000Free Float11,692,000Market Cap$219.34 million OptionableOptionable Beta2.56 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CRBP) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.